391 related articles for article (PubMed ID: 32215187)
1. Acute promyelocytic leukemia (APL): a review of the literature.
Jimenez JJ; Chale RS; Abad AC; Schally AV
Oncotarget; 2020 Mar; 11(11):992-1003. PubMed ID: 32215187
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
3. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
4. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
6. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
7. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
8. Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia.
Thomas X
Oncol Ther; 2019 Jun; 7(1):33-65. PubMed ID: 32700196
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.
McCulloch D; Brown C; Iland H
Onco Targets Ther; 2017; 10():1585-1601. PubMed ID: 28352191
[TBL] [Abstract][Full Text] [Related]
11. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
12. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
13. Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies.
Noguera NI; Catalano G; Banella C; Divona M; Faraoni I; Ottone T; Arcese W; Voso MT
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635329
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment strategies for newly diagnosed and relapsed APL].
Emi N
Rinsho Ketsueki; 2017; 58(10):1872-1877. PubMed ID: 28978827
[TBL] [Abstract][Full Text] [Related]
16. The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.
LaBella D; Regan S; Konig H; Egan DN; Bailey NA; Mawad R; Gilbert M; Pagel JM; Pu JJ
Front Oncol; 2022; 12():911745. PubMed ID: 35992790
[TBL] [Abstract][Full Text] [Related]
17. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells.
de Almeida LY; Pereira-Martins DA; Weinhäuser I; Ortiz C; Cândido LA; Lange AP; De Abreu NF; Mendonza SES; de Deus Wagatsuma VM; Do Nascimento MC; Paiva HH; Alves-Paiva RM; Bonaldo CCOM; Nascimento DC; Alves-Filho JC; Scheucher PS; Lima ASG; Schuringa JJ; Ammantuna E; Ottone T; Noguera NI; Araujo CL; Rego EM
Front Oncol; 2021; 11():686445. PubMed ID: 34650910
[TBL] [Abstract][Full Text] [Related]
18. Acute promyelocytic leukemia presenting as a paraspinal mass.
Shah NN; Stonecypher M; Gopal P; Luger S; Bagg A; Perl A
J Community Support Oncol; 2016 Mar; 14(3):126-9. PubMed ID: 27058871
[TBL] [Abstract][Full Text] [Related]
19. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
Hattori H; Ishikawa Y; Kawashima N; Akashi A; Yamaguchi Y; Harada Y; Hirano D; Adachi Y; Miyao K; Ushijima Y; Terakura S; Nishida T; Matsushita T; Kiyoi H
PLoS One; 2018; 13(10):e0204850. PubMed ID: 30289902
[TBL] [Abstract][Full Text] [Related]
20. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
